Breast cancer screening test

Breast cancer screening test Early detection of disease allows the best hope for healing with minimal intervention. The success of therapy often depends depends on the Spread (stage) and biological characteristics (degree and nature) of disease. they can deteriorate over time. A successful screening strategy should:

• Aimed at a disease that is commonly found and dangerous.
• Using screening tests are simple, safe inexpensive and valid.
• Allows curative therapy, which if started early to have a significant impact on life expectancy.

Although bersitat observational, cohort studies and randomized controlled trials (randomized controlled trial) has demonstrated the benefits some screening programs but still there are some problems:
• Screening can trigger anxiety.
• Screening may only increase the latent period (time before onset of symptoms)

Screening may only increase the detection of cancers are more indolent, which may never be clinically apparent. When inserted into the cancer that has clinical relevance, these cancers are apparently increases the percentage of cases of early and overall life expectancy. At the screening one of the earliest indications of reduced mortality in the future is the decline in absolute amount (not percentage) in cases with advanced stage disease.

The impact of screening has been limited by a very large target population. difficulty in follow-up, low compliance, and poor sensitivity test with a high number of false positives.

In 1963 conducted a randomized cancer screening test first time with melaktukan mammography in breast cancer, using death as the endpoint. This was followed by several studies that support this approach. It is clear that screening with mammography in women aged 50-69 years reduces breast cancer mortality by 30%. There is controversy regarding screening in women aged 40-49 years because:

• While breast cancer is the leading cause of death in women that age. However, the incidence and death rates were lower in this age group.
• To date, randomized controlled trials conducted memherikan too small for statistical results that are not in doubt.
• Sensitivity of mammography was lower in the denser breast tissue.
• There is a relative incidence of ductal carcinoma in situ (DCIS) is higher.

  
Risk factors for breast cancer

The determination that some genetically inherited breast cancer has raised questions about genetic screening. Currently, the examination of BRCA-1 and -2 may be offered to young women with a history of strong will of the family with breast and ovarian hanker occurring at a young age. The best treatment to those who found that genes are not clear although preventive surgery (mastectomy and oophorectomy and tamoxifen) appears promising.

Source: fkunhas